InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,304.46
(
0.34%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: None

Wednesday, 05/21/2008 9:51:19 PM

Wednesday, May 21, 2008 9:51:19 PM

Post# of 4764
Pfizer's IGFR patent on their IgG2 antibody. Reduced immunogenicity (sp?). IMHO, if you are targeting cancer with an antibody to a cell surface receptor(s), then you want an IgG1 antibody.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=AND&d=PTXT&s1=imclone&OS=imclone&RS=imclone

biophud
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up